This article was originally published in The Gray Sheet
Receives FDA market go-ahead for the FLU OIA rapid test for influenza, the firm reports Dec. 2. The test, which employs the company's proprietary optical immunoassay technology and can be used by physicians in their offices, is the only test on the market that can detect both influenza A and B within 20 minutes, according to BioStar. The recently acquired subsidiary of Thermo BioAnalysis ("The Gray Sheet" Sept. 7, p. 14) will share profits from the test with Biota Holdings Limited of Australia, which collaborated on the product's development
You may also be interested in...
The US Food and Drug Administration posted two device-related closeout letters in November.
Jazz and PharmaMar need to see what further data will be needed to convert their FDA authorization into a full approval following disappointing results in the ATLANTIS Phase III trial.
As arguments rage over whether the UK regulator has rushed its assessment of the Pfizer/BioNTech vaccine, the European Medicines Agency explains why its conditional marketing authorization approach is taking a little longer.